Mirum Pharmaceuticals, Inc.
Health
Performance
3.6
Risk
Sell
Buy
Curious about the Scores? Learn more.

Mirum Pharmaceuticals, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

30.12.2025
From average to promising. Starting to shine again.
18.12.2025
Calmer waters ahead. Risk signals cooling off.
12.12.2025
Outperforming hard. Momentum locked in.

Mirum Pharmaceuticals, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Mirum Pharmaceuticals, Inc. do? Business model and key facts

Get the full picture of Mirum Pharmaceuticals, Inc.: what it builds, where it operates, and how it makes money.

Mirum Pharmaceuticals, Inc. Profile

Sector: Healthcare

Industry: Biotechnology

Employees (FY): 334

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

shop
Company facts
Christopher Peetz
CEO
334
Employees worldwide
shop
Performance
99.27%
Last 12 months
403.38%
Last 5 years
shop
Growth
$336,89M
Revenue year
$-87.942.000
Net income
shop
Valuation
$4,56B
Market Cap
-22.35
Price/Earnings Ratio

Stocks related to Mirum Pharmaceuticals, Inc.

Selected based on industry alignment and relative market positioning.

TGTX
TG Therapeutics, Inc.
30.71
+3.96%
7.9
Sell
Buy
TG Therapeutics, Inc.
ALKS
Alkermes plc
31.22
+1.96%
5.7
Sell
Buy
Alkermes plc
PTGX
Protagonist Therapeutics, Inc.
84.75
-0.56%
7.7
Sell
Buy
Protagonist Therapeutics, Inc.
ACAD
ACADIA Pharmaceuticals Inc.
26.53
-1.23%
5.5
Sell
Buy
ACADIA Pharmaceuticals Inc.
FOLD
Amicus Therapeutics, Inc.
14.31
-0.49%
5.1
Sell
Buy
Amicus Therapeutics, Inc.

Mirum Pharmaceuticals, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.